Avacta Group plc reported strong operational progress in 2025, having raised £22.5m in equity to support its research and development programmes. The company ended the year with unaudited cash reserves
Genflow Biosciences Plc appointed Gad Berdugo as Independent Non-Executive Chairman
Genflow Biosciences Plc (LON: GENF) has appointed Gad Berdugo as Independent Non-Executive Chairman, a move intended to support the group’s next phase of corporate development and R&D expansion.
Shortwave Life Sciences (AQSE: PSY) Inside Shortwave January 2026
Dear Reader,
ValiRx plc (AIM: VAL) New Evaluation and Material Transfer Agreement
ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women’s health and The Royal Institute for the Advancement of Learning/McGill University (“McGill”), a Canadian based
Genflow Biosciences PLC (LON: GENF) A Review of an Exciting 2025
Genflow Biosciences PLC (LON: GENF) said it made solid operational progress during 2025, advancing multiple programmes across aging, metabolic disease and gene therapy, while laying the groundwork for a more
Avacta (AIM: AVCT) sees strong sentiment recovery in second half of 2025
Avacta (AIM: AVCT) has enjoyed a strong recovery in sentiment during the second half of 2025, with the share price rising from around 30 pence in early July to 58.00 pence
10 Companies to Watch in 2026
2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty.
Zak’s Traders Café: Top Performers of 2025 and Stocks to Watch in 2026
The Year Ahead
Six Biotechs to Watch in 2026: Breakthroughs, Setbacks, and Big Turning Points Ahead
The biotechnology market has delivered a mixed landscape in 2025, shaped by shifting investor sentiment, ongoing regulatory pressures, and the continued search for differentiated clinical assets. Against this backdrop several
hVIVO plc (AIM: HVO) Appointment of Richard Cotton as Non-Executive Director
hVIVO strengthens Board with appointment of Richard Cotton as Non-Executive Director Seasoned life sciences executive with extensive Board and financial expertise
Poolbeg Pharma (AIM: POLB) Letter to Shareholders – 2025 a year of progress
Letter to Shareholders – 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected
Avacta Therapeutics (AIM: AVCT) reports new AVA6103 pharmacology data
Avacta reports new pharmacology data for FAP-Exd (AVA6103) Multiple patient-derived xenograft models with prolonged complete responses associated with sustained release of the exatecan payload within the tumor over five days